18 Kasım 2026, Çarşamba · 07:36 Piyasalar Kapalı
borsapanel.com Borsanın nabzı, tek panelde.
Abone Ol

The Biotech Surged 50% On Positive Data In March. Now, It's Almost Gone.

Xenon Pharmaceuticals (XENE) voluntarily halted enrollment in a handful of studies Friday due to several unexpected side effects. The biotech stock crashed to a six-month low. The drug at the center of the debacle is azetukalner, which Xenon is hoping will soon gain approval to treat epilepsy. Xenon stock shot 50% higher on March 9 following positive results for azetukalner…

Kaynak: Yahoo Finance
İlgili Haberler
Global Putin says EU is losing industry, falling behind competition ahead of meeting with Trump, Xi CNBC Finance · 8 dk önce Global "Breaking Bad" dizisinin yıldızı Dean Norris, boşanma sürecindeyken 4,5 hektarlık Kaliforniya'daki mülkünü 3,2 milyon dolara satıyor MarketWatch Top · 18 saat önce Global Nvidia'dan Apple'a kadar ABD'li şirketler artan bir Çin ikilemiyle karşı karşıya CNBC Finance · 19 saat önce Global Berkshire Hathaway raised its stake in Delta in the third quarter. It also trimmed a key bank holding CNBC Finance · 1 gün önce Global JPMorgan Chase says temporary software bug is affecting consumer banking CNBC Finance · 1 gün önce

Yorumlar (0)

Giriş yaparak yorum yazabilirsin.

İlk yorumu sen yaz.